Get notified when VERU files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — The company explicitly warns that failure to secure financing could threaten its ability to continue as a going concern.
Veru launches at-the-market offering to sell up to $21.8M of common stock at $3.16/share
Filed July 2, 2026 · ~1 min read
Key Changes
-
high
Veru entered an at-the-market sales agreement to sell up to $21.8 million of common stock through Oppenheimer and Canaccord, with no minimum amount guaranteed.
The Offering verify on EDGAR → -
high
New investors pay $3.16 per share but receive only $1.63 in net tangible book value, an immediate dilution of $1.53 per share.
Dilution verify on EDGAR → -
medium
Net proceeds are earmarked for general corporate purposes, including working capital, R&D, clinical trials, and potential acquisitions, with broad management discretion.
Use of Proceeds verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (NTSK 10-Q) is open in full — no account needed.
Partner
Trade VERU commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify